Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

In recent years, there has been a significant increase in the number of patients with malignancies treated with immune checkpoint inhibitors (ICIs), including the anti-programmed cell death protein 1 (anti–PD-1) agent pembrolizumab. One of the important aspects of conducting clinical trials with ICI...

Full description

Bibliographic Details
Main Authors: M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2023-06-01
Series:Безопасность и риск фармакотерапии
Subjects:
pembroria
pembrolizumab
biosimilar
pd-1 inhibitor
immune-related adverse events
immune-mediated adverse reactions
immune-checkpoint inhibitors
immunotherapy
clinical trials
Online Access:https://www.risksafety.ru/jour/article/view/360

Similar Items

Similar Items